Company overview

Livzon Mabpharm Inc.

USCC

914404005573482907

Id2

440400000235288

English Name

Livzon Mabpharm Inc.

Former names

-

Chinese Name

珠海市丽珠单抗生物技术有限公司

Entity type

Limited Liability Company (Wholly Foreign-Owned Enterprise)

Authorized capital

¥145,333

Email

kuangyexiong@livzonbio.com

Phone

+867567238688

Representative

朱保国 (Zhu Bao Guo)

Establishment date

2 July 2010

Country

China

Primary goods traded

  • 💉82.9% — Blood, human or animal, antisera, other blood fractions and immunological products (300215)
  • 17.1% — Medicaments (300439)
Main Trading Partners
PartnerTypeTotal ValuePercentage
PT Kimia Farmabuyer$2,318,78682.88%
PT Lapi Laboratoriesbuyer$478,84117.12%
Loading chart...
Loading chart...
Loading chart...
Loading chart...
Trade Data
Data SourceHS CodeDescriptionBuyerBuyer CountrySellerSeller Country
5 August 2021ID30021500Tocilizumab Injection (Recombinant Humanized Anti-Human) Il-6r Monoclonal Antibody SolutionPT Perusahaan Perseroan Persero PT Kimia FarmaIDLivzon Mabpharm IncCN$1,181,684.15
6 August 2021ID30021500Tocilizumab Injection (Recombinant Humanized Anti-Human) Il-6r Monoclonal Antibody SolutionPT Perusahaan Perseroan Persero PT Kimia FarmaIDLivzon Mabpharm IncCN$1,137,102.00
15 October 2024ID30043900InfertreatPT Lapi LaboratoriesIDLivzon Mabpharm Inc$241,310.65
26 December 2023ID30043900InfertreatPT Lapi LaboratoriesIDLivzon Mabpharm Inc$237,530.63
0 of 4 row(s) selected.